Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 109

1.

Differential pharmacology and clinical utility of dapagliflozin in type 2 diabetes.

Papakitsou I, Vougiouklakis G, Elisaf MS, Filippatos TD.

Clin Pharmacol. 2019 Sep 19;11:133-143. doi: 10.2147/CPAA.S172353. eCollection 2019.

2.

Emerging Fixed-Dose Combination Treatments for Hyperlipidemia.

Pappa E, Rizos CV, Filippatos TD, Elisaf MS.

J Cardiovasc Pharmacol Ther. 2019 Jul;24(4):315-322. doi: 10.1177/1074248419838506. Epub 2019 Mar 25.

PMID:
30909733
3.

SGLT2 inhibitors and cardioprotection: a matter of debate and multiple hypotheses.

Filippatos TD, Liontos A, Papakitsou I, Elisaf MS.

Postgrad Med. 2019 Mar;131(2):82-88. doi: 10.1080/00325481.2019.1581971. Review.

PMID:
30757937
4.

Pleiotropic effects of proprotein convertase subtilisin/kexin type 9 inhibitors?

Filippatos TD, Christopoulou EC, Elisaf MS.

Curr Opin Lipidol. 2018 Aug;29(4):333-339. doi: 10.1097/MOL.0000000000000523. Review.

PMID:
29994840
5.

SGLT2 inhibitors and the kidney: Effects and mechanisms.

Tsimihodimos V, Filippatos TD, Elisaf MS.

Diabetes Metab Syndr. 2018 Nov;12(6):1117-1123. doi: 10.1016/j.dsx.2018.06.003. Epub 2018 Jun 6. Review.

PMID:
29909004
6.

Obesity and cardiovascular risk: a call for action from the European Society of Hypertension Working Group of Obesity, Diabetes and the High-risk Patient and European Association for the Study of Obesity: part B: obesity-induced cardiovascular disease, early prevention strategies and future research directions.

Kotsis V, Tsioufis K, Antza C, Seravalle G, Coca A, Sierra C, Lurbe E, Stabouli S, Jelakovic B, Redon J, Redon P, Nilsson PM, Jordan J, Micic D, Finer N, Leitner DR, Toplak H, Tokgozoglu L, Athyros V, Elisaf M, Filippatos TD, Grassi G.

J Hypertens. 2018 Jul;36(7):1441-1455. doi: 10.1097/HJH.0000000000001731.

PMID:
29652731
7.

Obesity and cardiovascular risk: a call for action from the European Society of Hypertension Working Group of Obesity, Diabetes and the High-risk Patient and European Association for the Study of Obesity: part A: mechanisms of obesity induced hypertension, diabetes and dyslipidemia and practice guidelines for treatment.

Kotsis V, Jordan J, Micic D, Finer N, Leitner DR, Toplak H, Tokgozoglu L, Athyros V, Elisaf M, Filippatos TD, Redon J, Redon P, Antza C, Tsioufis K, Grassi G, Seravalle G, Coca A, Sierra C, Lurbe E, Stabouli S, Jelakovic B, Nilsson PM.

J Hypertens. 2018 Jul;36(7):1427-1440. doi: 10.1097/HJH.0000000000001730. Review.

PMID:
29634663
8.

Novel Hypolipidaemic Drugs: Mechanisms of Action and Main Metabolic Effects.

Filippatos TD, Liontos A, Christopoulou EC, Elisaf MS.

Curr Vasc Pharmacol. 2019;17(4):332-340. doi: 10.2174/1570161116666180209112351.

PMID:
29424317
9.

Hypolipidemic Drugs and Diabetes Mellitus-Mechanisms and Data From Genetic Trials.

Filippatos TD, Panagiotopoulou T, Tzavella E, Elisaf MS.

J Cardiovasc Pharmacol Ther. 2018 May;23(3):187-191. doi: 10.1177/1074248418757011. Epub 2018 Feb 7. Review.

PMID:
29409336
10.

Non-hemorrhage-related adverse effects of rivaroxaban.

Christopoulou EC, Filippatos TD, Elisaf MS.

Arch Med Sci Atheroscler Dis. 2017 Dec 31;2:e108-e112. doi: 10.5114/amsad.2017.72533. eCollection 2017.

11.

Effects of increased body weight and short-term weight loss on serum PCSK9 levels - a prospective pilot study.

Filippatos TD, Liberopoulos E, Georgoula M, Tellis CC, Tselepis AD, Elisaf M.

Arch Med Sci Atheroscler Dis. 2017 Oct 5;2:e46-e51. doi: 10.5114/amsad.2017.70502. eCollection 2017.

12.

Pharmacokinetic drug evaluation of empagliflozin plus linagliptin for the treatment of type 2 diabetes.

Rizos CV, Filippatos TD, Elisaf MS.

Expert Opin Drug Metab Toxicol. 2018 Jan;14(1):117-125. doi: 10.1080/17425255.2018.1418325. Epub 2017 Dec 19. Review.

PMID:
29241374
13.

Hyponatremia in the elderly: challenges and solutions.

Filippatos TD, Makri A, Elisaf MS, Liamis G.

Clin Interv Aging. 2017 Nov 14;12:1957-1965. doi: 10.2147/CIA.S138535. eCollection 2017. Review.

14.

SGLT2 inhibitors: are they safe?

Filippas-Ntekouan S, Filippatos TD, Elisaf MS.

Postgrad Med. 2018 Jan;130(1):72-82. doi: 10.1080/00325481.2018.1394152. Epub 2017 Oct 27. Review.

PMID:
29039237
15.

Anacetrapib, a New CETP Inhibitor: The New Tool for the Management of Dyslipidemias?

Filippatos TD, Kei A, Elisaf MS.

Diseases. 2017 Sep 29;5(4). pii: E21. doi: 10.3390/diseases5040021. Review.

16.

Evacetrapib and cardiovascular outcomes: reasons for lack of efficacy.

Filippatos TD, Elisaf MS.

J Thorac Dis. 2017 Aug;9(8):2308-2310. doi: 10.21037/jtd.2017.07.75. No abstract available.

17.

SGLT2 inhibitors-induced electrolyte abnormalities: An analysis of the associated mechanisms.

Filippatos TD, Tsimihodimos V, Liamis G, Elisaf MS.

Diabetes Metab Syndr. 2018 Jan - Mar;12(1):59-63. doi: 10.1016/j.dsx.2017.08.003. Epub 2017 Aug 11. Review.

PMID:
28826578
18.

Effects of PCSK9 Inhibitors on Other than Low-Density Lipoprotein Cholesterol Lipid Variables.

Filippatos TD, Kei A, Rizos CV, Elisaf MS.

J Cardiovasc Pharmacol Ther. 2018 Jan;23(1):3-12. doi: 10.1177/1074248417724868. Epub 2017 Aug 22. Review.

PMID:
28826253
19.

PCSK9 and carbohydrate metabolism: A double-edged sword.

Filippatos TD, Filippas-Ntekouan S, Pappa E, Panagiotopoulou T, Tsimihodimos V, Elisaf MS.

World J Diabetes. 2017 Jul 15;8(7):311-316. doi: 10.4239/wjd.v8.i7.311.

20.

Gitelman syndrome: an analysis of the underlying pathophysiologic mechanisms of acid-base and electrolyte abnormalities.

Filippatos TD, Rizos CV, Tzavella E, Elisaf MS.

Int Urol Nephrol. 2018 Jan;50(1):91-96. doi: 10.1007/s11255-017-1653-4. Epub 2017 Jul 25. Review.

PMID:
28744758
21.

Modeling anthropometric indices in relation to 10-year (2002-2012) incidence of cardiovascular disease, among apparently healthy individuals: The ATTICA study.

Filippatos TD, Kyrou I, Georgousopoulou EN, Chrysohoou C, Kouli GM, Tsigos C, Tousoulis D, Stefanadis C, Pitsavos C, Panagiotakos DB.

Diabetes Metab Syndr. 2017 Dec;11 Suppl 2:S789-S795. doi: 10.1016/j.dsx.2017.05.018. Epub 2017 Jun 3.

PMID:
28606442
22.

Phosphate imbalance in patients with heart failure.

Christopoulou EC, Filippatos TD, Megapanou E, Elisaf MS, Liamis G.

Heart Fail Rev. 2017 May;22(3):349-356. doi: 10.1007/s10741-017-9615-6. Review.

PMID:
28432604
23.

Serum osmolal gap in clinical practice: usefulness and limitations.

Liamis G, Filippatos TD, Liontos A, Elisaf MS.

Postgrad Med. 2017 May;129(4):456-459. doi: 10.1080/00325481.2017.1308210. Epub 2017 Mar 23. Review.

PMID:
28306366
24.

Pharmacological management of diabetic dyslipidemia.

Filippatos TD, Florentin M, Georgoula M, Elisaf MS.

Expert Rev Clin Pharmacol. 2017 Feb;10(2):187-200. doi: 10.1080/17512433.2017.1263565. Epub 2016 Dec 2. Review.

PMID:
27868450
25.

Use of intravenous fluids/solutions: a narrative review.

El Gkotmi N, Kosmeri C, Filippatos TD, Elisaf MS.

Curr Med Res Opin. 2017 Mar;33(3):459-471. doi: 10.1080/03007995.2016.1261819. Epub 2016 Dec 14. Review.

PMID:
27848268
26.

Effects of sodium-glucose co-transporter 2 inhibitors on metabolism: unanswered questions and controversies.

Tsimihodimos V, Filippatos TD, Elisaf MS.

Expert Opin Drug Metab Toxicol. 2017 Apr;13(4):399-408. doi: 10.1080/17425255.2017.1258055. Epub 2016 Nov 17. Review.

PMID:
27819144
27.

Renoprotective Effects of SGLT2 Inhibitors: Beyond Glucose Reabsorption Inhibition.

Tsimihodimos V, Filippatos TD, Filippas-Ntekouan S, Elisaf M.

Curr Vasc Pharmacol. 2017;15(2):96-102. doi: 10.2174/1570161114666161007163426. Review.

PMID:
27748201
28.

MANAGEMENT OF ENDOCRINE DISEASE: Hypothyroidism-associated hyponatremia: mechanisms, implications and treatment.

Liamis G, Filippatos TD, Liontos A, Elisaf MS.

Eur J Endocrinol. 2017 Jan;176(1):R15-R20. Epub 2016 Aug 2. Review.

PMID:
27484454
29.

Hyponatremia in patients with liver diseases: not just a cirrhosis-induced hemodynamic compromise.

Liamis G, Filippatos TD, Liontos A, Elisaf MS.

Hepatol Int. 2016 Sep;10(5):762-72. doi: 10.1007/s12072-016-9746-1. Epub 2016 Jun 21. Review.

PMID:
27328847
30.

Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors.

Filippatos TD, Tsimihodimos V, Elisaf MS.

Expert Opin Pharmacother. 2016 Aug;17(12):1581-3. doi: 10.1080/14656566.2016.1201073. Epub 2016 Jun 24. No abstract available.

PMID:
27295549
31.

Cholesteryl ester transfer protein inhibitors: challenges and perspectives.

Filippatos TD, Klouras E, Barkas F, Elisaf M.

Expert Rev Cardiovasc Ther. 2016 Aug;14(8):953-62. doi: 10.1080/14779072.2016.1189327. Epub 2016 May 28. Review.

PMID:
27171534
32.

Thiazide-associated hyponatremia in the elderly: what the clinician needs to know.

Liamis G, Filippatos TD, Elisaf MS.

J Geriatr Cardiol. 2016 Feb;13(2):175-82. doi: 10.11909/j.issn.1671-5411.2016.02.001. Review.

33.

Ten pitfalls in the proper management of patients with hyponatremia.

Filippatos TD, Liamis G, Elisaf MS.

Postgrad Med. 2016 Jun;128(5):516-22. doi: 10.1080/00325481.2016.1186488. Epub 2016 May 24. Review.

PMID:
27153450
34.

Pitavastatin and carbohydrate metabolism: what is the evidence?

Filippatos TD, Elisaf MS.

Expert Rev Clin Pharmacol. 2016 Jul;9(7):955-60. doi: 10.1586/17512433.2016.1165607. Epub 2016 Mar 28. Review.

PMID:
26967972
35.

Electrolyte disorders associated with the use of anticancer drugs.

Liamis G, Filippatos TD, Elisaf MS.

Eur J Pharmacol. 2016 Apr 15;777:78-87. doi: 10.1016/j.ejphar.2016.02.064. Epub 2016 Mar 3. Review.

PMID:
26939882
36.

The safety of ezetimibe and simvastatin combination for the treatment of hypercholesterolemia.

Kei AA, Filippatos TD, Elisaf MS.

Expert Opin Drug Saf. 2016;15(4):559-69. doi: 10.1517/14740338.2016.1157164. Epub 2016 Mar 16. Review.

PMID:
26898906
37.

Evaluation and treatment of hypernatremia: a practical guide for physicians.

Liamis G, Filippatos TD, Elisaf MS.

Postgrad Med. 2016;128(3):299-306. doi: 10.1080/00325481.2016.1147322. Epub 2016 Feb 23. Review.

PMID:
26813151
38.

Mediterranean Diet and 10-year (2002-2012) Incidence of Diabetes and Cardiovascular Disease in Participants with Prediabetes: The ATTICA study.

Filippatos TD, Panagiotakos DB, Georgousopoulou EN, Pitaraki E, Kouli GM, Chrysohoou C, Tousoulis D, Stefanadis C, Pitsavos C; ATTICA Study Group.

Rev Diabet Stud. 2016 Winter;13(4):226-235. doi: 10.1900/RDS.2016.13.226. Epub 2017 Feb 10.

39.

Ten common pitfalls in the evaluation of patients with hyponatremia.

Filippatos TD, Liamis G, Christopoulou F, Elisaf MS.

Eur J Intern Med. 2016 Apr;29:22-5. doi: 10.1016/j.ejim.2015.11.022. Epub 2015 Dec 17. Review.

PMID:
26706473
40.

Effects of ezetimibe/simvastatin combination on metabolic parameters.

Filippatos TD, Elisaf MS.

Int J Cardiol. 2016 Jan 1;202:273-4. doi: 10.1016/j.ijcard.2015.08.130. Epub 2015 Sep 12. No abstract available.

PMID:
26408840
41.

Statin-Ezetimibe Combination Therapy In Diabetic Individuals.

Filippatos TD, Elisaf MS.

Angiology. 2016 Jul;67(6):507-9. doi: 10.1177/0003319715598887. Epub 2015 Aug 14. No abstract available.

PMID:
26275885
42.

Adverse Effects of GLP-1 Receptor Agonists.

Filippatos TD, Panagiotopoulou TV, Elisaf MS.

Rev Diabet Stud. 2014 Fall-Winter;11(3-4):202-30. doi: 10.1900/RDS.2014.11.202. Epub 2015 Feb 10. Review.

43.

Safety considerations with fenofibrate/simvastatin combination.

Filippatos TD, Elisaf MS.

Expert Opin Drug Saf. 2015;14(9):1481-93. doi: 10.1517/14740338.2015.1056778. Epub 2015 Jul 3. Review.

PMID:
26134595
44.

Current lipid-modifying agents.

Agouridis AP, Filippatos TD, Katsiki N.

Expert Opin Pharmacother. 2015 May;16(7):1117-8. doi: 10.1517/14656566.2015.1035013. Epub 2015 Apr 6. No abstract available.

PMID:
25845932
45.

Correction of hypovolemia with crystalloid fluids: Individualizing infusion therapy.

Liamis G, Filippatos TD, Elisaf MS.

Postgrad Med. 2015 May;127(4):405-12. doi: 10.1080/00325481.2015.1029421. Epub 2015 Mar 26. Review.

PMID:
25812486
46.

Are lower levels of LDL-cholesterol really better? Looking at the results of IMPROVE-IT: opinions of three experts - III.

Filippatos TD, Elisaf MS.

Hellenic J Cardiol. 2015 Jan-Feb;56(1):7-9. No abstract available.

47.

Dapagliflozin in patients with type 2 diabetes mellitus.

Filippatos TD, Liberopoulos EN, Elisaf MS.

Ther Adv Endocrinol Metab. 2015 Feb;6(1):29-41. doi: 10.1177/2042018814558243. Review.

48.

Treatment of hyponatremia: the role of lixivaptan.

Liamis G, Filippatos TD, Elisaf MS.

Expert Rev Clin Pharmacol. 2014 Jul;7(4):431-41. doi: 10.1586/17512433.2014.911085. Epub 2014 Apr 28. Review.

PMID:
24766294
49.

The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected].

Filippatos TD, Athyros VG, Elisaf MS.

Expert Opin Drug Metab Toxicol. 2014 Jun;10(6):787-812. doi: 10.1517/17425255.2014.907274. Epub 2014 Apr 19. Review. Erratum in: Expert Opin Drug Metab Toxicol. 2014 Oct;10(10):1455.

PMID:
24746233
50.

Does combination therapy with statins and fibrates prevent cardiovascular disease in diabetic patients with atherogenic mixed dyslipidemia?

Agouridis AP, Rizos CV, Elisaf MS, Filippatos TD.

Rev Diabet Stud. 2013 Summer-Fall;10(2-3):171-90. doi: 10.1900/RDS.2013.10.171. Epub 2013 Aug 10. Review.

Supplemental Content

Loading ...
Support Center